Your session is about to expire
← Back to Search
SY-2101 for Acute Promyelocytic Leukemia
Study Summary
This trial is studying SY-2101, an oral formulation of a drug called arsenic trioxide, as a treatment for participants with a type of leukemia called acute promyelocytic leukemia (APL).
- Acute Promyelocytic Leukemia
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2009 Phase 2 trial • 22 Patients • NCT00024258Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Multiple-Dose IV Module
- Group 2: Multiple-Dose Oral Module
- Group 3: Single-Dose PK Module: Sequence 1
- Group 4: Single-Dose PK Module: Sequence 2
- Group 5: Single-Dose PK Comparability Module
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there vacancies available for those who wish to participate in this research?
"Indeed. According to the details hosted on clinicaltrials.gov, recruitment for this trial is still underway - it was initially posted on September 17th 2021 and last edited July 12th 2022. In total 24 participants are needed across 5 different medical facilities."
Are there any precedent investigations involving SY-2101?
"Currently, 14 trials of SY-2101 are taking place with 3 reaching the last stage. Most notably, Guangzhou in Guangdong is one of 234 locations studying this drug's efficacy and safety."
Do any of the research facilities in the US have this trial underway?
"Enrolment to this clinical trial is possible at 5 locations, such as Clinical Trial Site 4 in Ann Arbor and Clinical Trial Site 2 in Birmingham. Also available are facilities like Clinical Trial site 1 in Houston among other centres."
Has the Federal Drug Administration sanctioned SY-2101?
"Due to the lack of real-world evidence, SY-2101's safety rating is a 1. This Phase 1 trial only provides preliminary data regarding efficacy and safety profiles."
Share this study with friends
Copy Link
Messenger